<?xml version='1.0' encoding='utf-8'?>
<document id="29239000"><sentence text="Minimal Physiologically Based Pharmacokinetic and Drug-Drug-Disease Interaction Model of Rivaroxaban and Verapamil in Healthy and Renally Impaired Subjects."><entity charOffset="89-100" id="DDI-PubMed.29239000.s1.e0" text="Rivaroxaban" /><entity charOffset="105-114" id="DDI-PubMed.29239000.s1.e1" text="Verapamil" /><pair ddi="false" e1="DDI-PubMed.29239000.s1.e0" e2="DDI-PubMed.29239000.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29239000.s1.e0" e2="DDI-PubMed.29239000.s1.e1" /></sentence><sentence text="Current dosing recommendations for rivaroxaban advocate dosage reduction in patients with moderate to severe renal impairment and avoidance of concomitant strong inhibitors of CYP3A or P-glycoprotein"><entity charOffset="35-46" id="DDI-PubMed.29239000.s2.e0" text="rivaroxaban" /></sentence><sentence text=" However, rivaroxaban dosing in patients with mild renal impairment taking concomitant moderate inhibitors of CYP3A and P-glycoprotein is not addressed"><entity charOffset="10-21" id="DDI-PubMed.29239000.s3.e0" text="rivaroxaban" /></sentence><sentence text=" To quantify the impacts of concomitant verapamil administration and renal impairment on rivaroxaban pharmacokinetics, a minimal physiologically based pharmacokinetic model system was developed and used to evaluate potential increases in rivaroxaban exposure and the consequent increase in risk of major bleeding"><entity charOffset="89-100" id="DDI-PubMed.29239000.s4.e0" text="rivaroxaban" /><entity charOffset="238-249" id="DDI-PubMed.29239000.s4.e1" text="rivaroxaban" /><pair ddi="false" e1="DDI-PubMed.29239000.s4.e0" e2="DDI-PubMed.29239000.s4.e0" /><pair ddi="false" e1="DDI-PubMed.29239000.s4.e0" e2="DDI-PubMed.29239000.s4.e1" /></sentence><sentence text=" Data from a phase 1, drug-drug interaction study were used to qualify the minimal physiologically based pharmacokinetic model system" /><sentence text=" Model-based simulations indicate that coadministration of rivaroxaban with verapamil substantially increases rivaroxaban exposure across all renal function categories, resulting in an exponential increase in bleeding risk"><entity charOffset="59-70" id="DDI-PubMed.29239000.s6.e0" text="rivaroxaban" /><entity charOffset="76-85" id="DDI-PubMed.29239000.s6.e1" text="verapamil" /><entity charOffset="110-121" id="DDI-PubMed.29239000.s6.e2" text="rivaroxaban" /><pair ddi="false" e1="DDI-PubMed.29239000.s6.e0" e2="DDI-PubMed.29239000.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29239000.s6.e0" e2="DDI-PubMed.29239000.s6.e1" /><pair ddi="false" e1="DDI-PubMed.29239000.s6.e0" e2="DDI-PubMed.29239000.s6.e2" /><pair ddi="false" e1="DDI-PubMed.29239000.s6.e1" e2="DDI-PubMed.29239000.s6.e1" /><pair ddi="false" e1="DDI-PubMed.29239000.s6.e1" e2="DDI-PubMed.29239000.s6.e2" /></sentence><sentence text=" Reduction of the daily rivaroxaban dose to 10 to 15 mg reduces the major bleeding risk below the designated 4"><entity charOffset="24-35" id="DDI-PubMed.29239000.s7.e0" text="rivaroxaban" /></sentence><sentence text="5% threshold in the majority of patients with normal or mildly impaired renal function" /><sentence text=" A reduction to 10 mg daily in patients with moderate to severe renal impairment provides additional risk reduction so that 90% of those patients fall below the 4" /><sentence text="5% threshold" /><sentence text=" A risk threshold of 4" /><sentence text="5% was selected because it is the median predicted risk in patients treated concomitantly with ketoconazole, which is contraindicated for use with rivaroxaban"><entity charOffset="95-107" id="DDI-PubMed.29239000.s12.e0" text="ketoconazole" /><entity charOffset="147-158" id="DDI-PubMed.29239000.s12.e1" text="rivaroxaban" /><pair ddi="false" e1="DDI-PubMed.29239000.s12.e0" e2="DDI-PubMed.29239000.s12.e0" /><pair ddi="false" e1="DDI-PubMed.29239000.s12.e0" e2="DDI-PubMed.29239000.s12.e1" /></sentence><sentence text=" Patients taking both rivaroxaban and verapamil should take a reduced daily dose of rivaroxaban to minimize bleeding risk"><entity charOffset="22-33" id="DDI-PubMed.29239000.s13.e0" text="rivaroxaban" /><entity charOffset="38-47" id="DDI-PubMed.29239000.s13.e1" text="verapamil" /><entity charOffset="84-95" id="DDI-PubMed.29239000.s13.e2" text="rivaroxaban" /><pair ddi="false" e1="DDI-PubMed.29239000.s13.e0" e2="DDI-PubMed.29239000.s13.e0" /><pair ddi="false" e1="DDI-PubMed.29239000.s13.e0" e2="DDI-PubMed.29239000.s13.e1" /><pair ddi="false" e1="DDI-PubMed.29239000.s13.e0" e2="DDI-PubMed.29239000.s13.e2" /><pair ddi="false" e1="DDI-PubMed.29239000.s13.e1" e2="DDI-PubMed.29239000.s13.e1" /><pair ddi="false" e1="DDI-PubMed.29239000.s13.e1" e2="DDI-PubMed.29239000.s13.e2" /></sentence><sentence text="" /></document>